Evidence map›Paper›PMID 9989957›Full record

Trial reportCirculation1999

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.

C M Ballantyne, J A Herd, L L Ferlic, J K Dunn, J A Farmer, P H Jones, J R Schein, A M Gotto

Registry-linked trialOpen access · bronzeAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00127218 (HDL Increased Plaque Stabilization in the Elderly), which is not on this map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00127218 phase3completedstarted 2003, after this paper: background citation

HDL Increased Plaque Stabilization in the Elderly

Ran2003Enrolled145Registered outcomes2Posted comparisons0ConditionsAtherosclerosis, Cardiovascular DiseaseArmsany statin, niacin, Placebo
PMID 11757504PMID 9761083other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 198 citations in OpenAlex.

  1. Fluvastatin for lowering lipids.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

C M BallantyneBaylor College of Medicine, Houston, Tex. 77030, USA. cmb@bcm.tmc.edu
J A Herd
L L Ferlic
J K Dunn
J A Farmer
P H Jones
J R Schein
A M Gotto
Tris Pharma (United States) · US

Funding

ZINC THERAPY IN SEXUAL DYSFUNCTION ON E S R D. PATIENTS ON HEMODIALYSISM01RR000350 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI GOODGAME, RICHARD W · 1985 to 1994
–
NCRR NIH HHS 5M01RR00350
6 · The paper itself

Abstract

BACKGROUND--Patients with coronary artery disease (CAD) commonly have low HDL cholesterol (HDL-C) and mildly elevated LDL cholesterol (LDL-C), leading to uncertainty as to whether the appropriate goal of therapy should be lowering LDL-C or raising HDL-C. METHODS AND RESULTS--Patients in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) had mildly to moderately elevated LDL-C; many also had low HDL-C, providing an opportunity to compare angiographic progression and the benefits of the HMG-CoA reductase inhibitor fluvastatin in patients with low versus patients with higher HDL-C. Of the 339 patients with biochemical and angiographic data, 68 had baseline HDL-C <0.91 mmol/L (35 mg/dL), mean 0.82+/-0.06 mmol/L (31. 7+/-2.2 mg/dL), versus 1.23+/-0.29 mmol/L (47.4+/-11.2 mg/dL) in patients with baseline HDL-C >/=0.91 mmol/L. Among patients on placebo, those with low HDL-C had significantly more angiographic progression than those with higher HDL-C. Fluvastatin significantly reduced progression among low-HDL-C patients: 0.065+/-0.036 mm versus 0.274+/-0.045 mm in placebo patients (P=0.0004); respective minimum lumen diameter decreases among higher-HDL-C patients were 0. 036+/-0.021 mm and 0.083+/-0.019 mm (P=0.09). The treatment effect of fluvastatin on minimum lumen diameter change was significantly greater among low-HDL-C patients than among higher-HDL-C patients (P=0.01); among low-HDL-C patients, fluvastatin patients had improved event-free survival compared with placebo patients. CONCLUSIONS--Although the predominant lipid-modifying effect of fluvastatin is to decrease LDL-C, patients with low HDL-C received the greatest angiographic and clinical benefit.

Indexed as

AdultAgedAngina, UnstableAngioplasty, Balloon, CoronaryApolipoproteinsCholesterol, HDLCholesterol, LDLCoronary AngiographyCoronary Artery BypassCoronary DiseaseDouble-Blind MethodFatty Acids, MonounsaturatedFemaleFluvastatinFollow-Up StudiesHumansApolipoproteinsCholesterol, HDLCholesterol, LDLFatty Acids, MonounsaturatedFluvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsIndoles

Identifiers

PMID9989957
OpenAlexW2033762664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.